Core Viewpoint - CONMED Corporation is positioned for growth due to its diverse product offerings and strong recurring revenue base, particularly in General Surgery, despite facing supply chain challenges and data security threats [1][2]. Group 1: Financial Performance - CONMED has a market capitalization of $2.26 billion and projects a 19.3% earnings growth for fiscal 2025 [2]. - The company has surpassed earnings estimates in three of the last four quarters, with an average surprise of 3.71% [2]. - The Zacks Consensus Estimate for earnings in 2024 has improved by 1% to $4.03 per share, with projected fourth-quarter revenues of $341.3 million, indicating growth of 4.3% year-over-year [12]. Group 2: Product and Market Position - CONMED's General Surgery segment is gaining traction with unique products like the Anchor Tissue Retrieval bag, contributing to a 3.6% revenue increase at constant exchange rates in Q3 2024 [4]. - The company has a broad product spectrum across various specialties, including orthopedics and gastroenterology, with key innovations like Hi-Fi Tape and the IM8000 surgical visualization system [6][7]. - Approximately 85% of CONMED's revenues come from recurring sales of single-use disposable products, which are increasingly preferred by healthcare facilities [8]. Group 3: Market Challenges - Supply chain constraints and data security threats are ongoing challenges for CONMED, potentially impacting operational stability and financial performance [1][11]. - The U.S. foot and ankle business may face sales declines due to the impact of hurricanes Helene and Milton, which caused procedure rescheduling [5].

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7] Value Score - The Value Score identifies attractive and discounted stocks using various financial ratios, appealing to value investors [4] Growth Score - The Growth Score emphasizes a company's financial health and future outlook, focusing on projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like recent price changes and earnings estimate shifts [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] Stock Selection Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering earnings outlook changes [10][11][12] Company Spotlight: CONMED Corporation - CONMED Corporation, based in Utica, N.Y., specializes in surgical instruments and devices for minimally invasive procedures, employing approximately 3,600 individuals [13] - Currently rated 3 (Hold) by Zacks, CONMED has a VGM Score of A and a Value Style Score of A, with a forward P/E ratio of 18.32, indicating strong valuation metrics [14] - Recent earnings estimates for fiscal 2024 have been revised upward, with the Zacks Consensus Estimate increasing by $0.04 to $4.03 per share, alongside an average earnings surprise of 3.7% [14] - Given its solid Zacks Rank and favorable Style Scores, CONMED is recommended for investors' consideration [15]

Core Insights - The article discusses the Zacks Premium service, which provides tools and resources for investors to make informed decisions in the stock market [1][2] Zacks Style Scores - Zacks Style Scores are guidelines that rate stocks based on value, growth, and momentum characteristics, helping investors identify securities likely to outperform the market in the short term [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Categories of Style Scores - **Value Score**: Focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [5] - **Growth Score**: Evaluates stocks based on projected earnings and sales growth, targeting companies with strong financial health [6] - **Momentum Score**: Assesses stocks based on price trends and earnings estimate changes, aiming to capitalize on market momentum [7] - **VGM Score**: Combines the three Style Scores to identify stocks with attractive value, growth, and momentum [8] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios [9] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [10] Stock Selection Strategy - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [12] - The direction of earnings estimate revisions is crucial; stocks with lower ranks but high Style Scores may still face downward price pressure [13] Company Spotlight: CONMED Corporation - CONMED Corporation, based in Utica, N.Y., specializes in surgical instruments and devices for minimally invasive procedures, employing approximately 3,600 people [15] - Currently rated 3 (Hold) with a VGM Score of A, CONMED shows a Growth Style Score of B, indicating a projected year-over-year earnings growth of 16.8% for the current fiscal year [16] - The Zacks Consensus Estimate for CONMED's earnings has increased by $0.04 to $4.03 per share, with an average earnings surprise of 3.7% [16][17]

Company Overview - CONMED Corporation is a major medical products manufacturer specializing in surgical instruments and devices for minimally invasive procedures and monitoring [11] - The company is headquartered in Utica, N.Y., employs approximately 3,600 people, and operates several manufacturing facilities [11] Investment Insights - CONMED has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid overall rating [11] - The company has a Momentum Style Score of B, with shares increasing by 10% over the past four weeks [12] - Six analysts have revised their earnings estimates higher for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.04 to $4.03 per share [12] - CONMED has an average earnings surprise of 3.7%, suggesting a positive outlook for earnings performance [12] Style Scores and Zacks Rank - The Zacks Rank and Style Scores are designed to help investors identify stocks with the best chances of outperforming the market [6][9] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for higher probability of success [9][10]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

CONMED Corporation (CNMD) delivered third-quarter 2024 adjusted earnings per share (EPS) of $1.05, which beat the Zacks Consensus Estimate of 99 cents by 6.1%. The bottom line improved 16.7% from the year-ago level.GAAP EPS for the quarter was $1.57 compared with 50 cents in the year-ago period.The company’s shares have lost 40.4% so far this years compared with the industry’s decline of 1.5%. The broader S&P 500 Index has gained 22.9% in the same time frame.Image Source: Zacks Investment ResearchRevenues i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the ...

Financial Data and Key Metrics Changes - Total sales for Q3 2024 were $316.7 million, a year-over-year increase of 4% as reported and 4.3% in constant currency [7] - GAAP net income for Q3 2024 was $49 million, compared to $15.8 million in Q3 2023, while adjusted net income increased 15% year-over-year to $32.7 million [8][32] - Adjusted diluted net earnings per share were $1.05, reflecting a 16.7% increase year-over-year [8][32] - Adjusted gross margin for Q3 was 56.5%, an increase of 60 basis points compared to the prior year [31] Business Line Data and Key Metrics Changes - U.S. orthopedic sales increased by 7.4%, while international orthopedic sales grew by 3.9% [26] - General Surgery revenue increased by 3.6% globally, with U.S. revenue growing by 7.4% but international revenue declining by 5% [28] - AirSeal capital sales in the U.S. continued strong growth, with no slowdown in demand for disposables [21][29] Market Data and Key Metrics Changes - U.S. sales increased by 7.4% compared to the prior year, while international sales grew by only 0.2% [26] - The orthopedic business showed resilience with a 5.2% growth worldwide, despite challenges in the supply chain [26] Company Strategy and Development Direction - The company is focused on improving service levels in the sports medicine space and addressing supply chain issues in orthopedics [27][23] - A succession plan was announced, with Pat Beyer set to take over as CEO, emphasizing a commitment to innovation and customer engagement [14][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of Hurricanes Helene and Milton on operations and production, which may affect Q4 results [24][35] - The company expects Q4 revenue to be between $339 million and $344 million, with full-year guidance adjusted to between $1.300 billion and $1.305 billion [37] Other Important Information - The company reported a cash balance of $38.5 million at the end of the quarter, an increase from $28.9 million [33] - Long-term debt decreased to $940 million, with a leverage ratio of 3.6 times [34] Q&A Session Summary Question: General Surgery performance and capital equipment revenues - Management explained that the decline in capital equipment revenues was due to last year's strong performance and backorders being resolved [40][41] Question: Orthopedic supply situation and future impact - Management confirmed progress in supply chain improvements but acknowledged that challenges may extend into 2025 [43][46] Question: Top priorities for 2025 - The new CEO emphasized focusing on customer engagement, employee connection, and advancing the company's growth [56] Question: Impact of IV fluid shortages on procedures - Management confirmed that hospitals have started reallocating and deferring procedures due to shortages, which has been factored into guidance [57] Question: Outlook for gross margins - Management expressed confidence in maintaining gross margin improvements, with expectations for Q4 around 57% [59] Question: Contingent consideration adjustments - Management clarified that adjustments were related to slower-than-expected performance in the foot and ankle business, but overall confidence in acquisitions remains strong [60][61]

For the quarter ended September 2024, Conmed (CNMD) reported revenue of $316.7 million, up 4% over the same period last year. EPS came in at $1.05, compared to $0.90 in the year-ago quarter. The reported revenue represents a surprise of -0.55% over the Zacks Consensus Estimate of $318.46 million. With the consensus EPS estimate being $0.99, the EPS surprise was +6.06%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 6.06%. A quarter ago, it was expected that this medical technology company would post earnings of $0.92 per share when it actually produced earnings of $0.98, delivering a surprise of 6.52%. Over the last four quarters, the ...